Year All 2026 2025 2024 2021 BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results September 18, 2026 BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer September 15, 2026 BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference September 3, 2026 BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer September 1, 2026 BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC August 18, 2026 BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering August 6, 2026 BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026 June 11, 2026 BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting May 21, 2026 BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid May 20, 2026 BlossomHill Therapeutics to Present Initial Clinical Dose Escalation Data from the Phase 1/1b Trial of BH-30236 in Patients with R/R AML or HR-MDS at EHA2026 May 12, 2026
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer September 15, 2026
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference September 3, 2026
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer September 1, 2026
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC August 18, 2026
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering August 6, 2026
BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026 June 11, 2026
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting May 21, 2026
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid May 20, 2026
BlossomHill Therapeutics to Present Initial Clinical Dose Escalation Data from the Phase 1/1b Trial of BH-30236 in Patients with R/R AML or HR-MDS at EHA2026 May 12, 2026